|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Author** | **Study Design** | **Study Period** | **Study Location** | **Number of NAFLD-HCC Cases** | a**Treatment** | **Survival Outcomes** |
| **Overall Survival** | **Disease-Free Survival** |
| Reddy et al. | Retrospective cohort | 2000-2010 | Single-centered (United States) | 52 | OLT, bresection, RFA | c1-year: 90%c3-year: 72%c5-year: 65% | c1-year: 84%c3-year: 70%c5-year: 60% |
| Wong et al. | Retrospective cohort | 2002-2012 | Multi-centered (United States) | dData not available | OLT | 1-year: 87.5%3-year: 79.8%5-year: 65.5% | Data not available |
| Piscaglia et al. | Prospective cohort | 2010-2012 | Multi-centered (Italy) | 49 | OLT, resection, RFA | c1-year: 90-95%c3-year: 85-90% | Data not available |
| Malik et al. | Retrospective cohort | Data not available | Single-centered (United States) | 17 | OLT | c1-year: 85-90% | Data not available |
| Hernandez-Alejandro et al. | Retrospective cohort | 2000-2011 | Single-centered (Canada) | 17 | OLT | Data not available | c1-year: 95%c3-year: 95%c5-year: 85% |
| Cauchy et al. | Retrospective cohort | 2000-2011 | Single-centered (France) | e62 | Resection | 1-year: 83%3-year: 75% | 1-year: 83%3-year: 70% |
| Wakai et al. | Retrospective cohort | 1990-2007 | Single-centered (Japan) | 17 | Resection | 5-year: 59% | 5-year: 66% |
| Takuma et al. | Retrospective cohort | 1992-2009 | Two-centered (Japan) | f36 | Resection, RFA, PEI, MCT | 1-year: 94%3-year: 85%5-year: 54% | 1-year: 89%3-year: 68%5-year: 54% |

Review Article

**Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)**

Carrie R. Wong1, Mindie H. Nguyen2, and Joseph K. Lim\*3

1Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA; 2Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA, USA; 3Yale Liver Center, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, USA

**Running/Short Title**: Wong C.R. *et al*: Liver Cancer in Patients with Fatty Liver Disease

**Keywords**： Fatty liver; nonalcoholic steatohepatitis; hepatocellular carcinoma; liver cirrhosis; liver cancer.

**Abbreviations:** HCC, hepatocellular carcinoma; U.S., United States; SEER, Surveillance, Epidemiology, and End Results; HCV, hepatitis C virus; NAFLD, nonalcoholic fatty liver disease; VA, Veterans Administration; HBV, hepatitis B virus; ALD, alcoholic liver disease; PNPLA3, patatin-like phospholipase domain-containing protein 3; IGF-1, insulin-like growth factor-1; M6P/IGF2R, mannose 6-phosphate/insulin-like growth factor-2 receptor; IRS-1, insulin receptor substrate-1; FFA, free fatty acids; ROS, reactive oxidative species; JNK1, c-Jun amino-terminal kinase 1; TNF-α, tumor necrosis factor-alpha; IL-6, interleukin-6; STAT3, signal transducer and activator of transcription; BCLC, Barcelona Clinic Liver Cancer; OLT, orthotopic liver transplantation; RFA, radiofrequency ablation; UNOS, United Network for Organ Sharing; NASH, non-alcoholic steatohepatitis; SRTR, Scientific Registry of Transplant Recipients; NAS, NAFLD activity score; BMI, body mass index.

\***Correspondence to:** Joseph K. Lim, Yale Liver Center, Section of Digestive Diseases, Yale University School of Medicine, 333 Cedar Street, LMP 1080, New Haven, CT 06520-8019, USA. Tel: +1- 203-737-6063, Fax: +1-203-785-7273, E-mail: joseph.lim@yale.edu

**Conflict of interest:** None

**Author contributions:** Drafting of the manuscript (CRW), contributing to the conception and design (CRW, MHN, JKL), contributing to critical revisions of the manuscript (MHN, JKL)

**Abstract**

Nonalcoholic fatty liver disease is the most common chronic liver disease in the United States and represents an increasing important etiology of hepatocellular carcinoma (HCC) with annual cumulative incidence rates ranging from 2 to12% in cohorts of NAFLD cirrhosis. While the risk of progression of NAFLD to HCC remains higher among patients with fibrosis or cirrhosis, an increasing amount of literature describes NAFLD-HCC as a disease that can occur in the absence of cirrhosis. Efforts to characterize the pathogenesis of NAFLD-HCC have suggested mechanisms that strongly associate with states of hyperinsulinemia and chronic inflammation, genetic polymorphisms including mutations of PNPLA3, and adaptive immune responses such as selective CD4+ T lymphocyte loss. Current literature describes NAFLD-HCC mostly as a disease of late presentation with lower rates of receipt of curative therapy and worse prognosis. However, a growing body of evidence has reported comparable and potentially more favorable disease-free and overall survival rates among patients with NAFLD-HCC after receipt of curative treatment. This review summarizes current evidence of epidemiology, pathophysiology, disease presentation, demand and receipt of curative therapy, and post-treatment outcomes of NAFLD-associated HCC.

**Epidemiology**

Hepatocellular carcinoma (HCC) is the fifth most prevalent cancer and third most common cause of cancer-related mortality worldwide (1-3). In the United States (U.S.), the overall incidence of HCC has increased approximately four-fold from 1.5 cases per 100,000 in 1973 to 6.2 cases per 100,000 in 2011 (3). Rates of mortality are similar to rates of incidence of HCC in the U.S. (1, 3). Based on recent analysis using the Surveillance, Epidemiology, and End Results (SEER) 18 database, the estimated annual incidence of HCC is 6.2 cases per 100,000 and the incidence-based mortality rate is 5 cases per 100,000 (3). A recent U.S. report revealed that while the overall rate of cancer-related deaths has declined, mortality from liver cancer has increased at the highest rate as compared with all other reported cancers from 2003 to 2012 (4). While most cases of HCC in the U.S. are attributable to chronic hepatitis C virus (HCV) infection, there has been growing evidence to suggest that nonalcoholic fatty liver disease (NAFLD) is projected to become a leading cause of HCC incidence and mortality (5-7). A recent study by Younossi et al. revealed that the annual incidence of NAFLD-HCC based on a SEER-Medicare cohort has grown by 9% per year from 2004 to 2009 (7).

The prevalence of NAFLD-HCC is expected to rise in concurrence with the proportion of NAFLD among adults in the U.S. population. In the Western world, NAFLD is already the most common chronic liver condition with an estimated prevalence of 30% in the US, although a previous cohort has reported a prevalence as high as 46% (6, 8-10). The prevalence of NAFLD will continue to grow in a setting of increasing rates of obesity, diabetes, dyslipidemia, and other disorders associated with the metabolic syndrome which are closely related to NAFLD (6, 8-16).

The risk of progression to cirrhosis among patients with NAFLD is approximately 4 to 20% depending on the severity of necrosis and fibrosis (6, 17). Although the risk of developing NAFLD-HCC from NAFLD cirrhosis is not clearly delineated, the cumulative incidence of HCC from NAFLD cirrhosis has been reported as 2.4% and 12.8% over a median follow-up of 3.2 to 7.2 years (16, 18, 19). A large single-center cohort study reported an annual HCC incidence of 2.6% among patients with NAFLD cirrhosis (18).

*NAFLD-HCC without Cirrhosis*

While previous studies have described fibrosis progression in NAFLD and its risk of cirrhosis and HCC, recent reports increasingly recognize NAFLD-HCC as an entity that can occur in the absence of cirrhosis (6, 16, 20-26). In fact, up to 50% of incident NAFLD-HCC may occur without cirrhosis (6, 27). In a recent Veterans Administration (VA) study, 34.6% of patients with NAFLD-HCC did not have diagnostic evidence of cirrhosis (23). Notably, liver biopsy was performed in 52.4% of the study cohort (23). While only 8% of patients in this cohort had NAFLD, the study demonstrated that patients with NAFLD had the greatest odds of developing HCC in the absence of cirrhosis in comparison to other etiologies including chronic hepatitis B (HBV), HCV, and alcoholic liver disease (ALD) (adjusted odds ratio 3.9 when compared with HCV) (23). Another large U.S. study comprised of three tertiary care centers identified 157 patients, who underwent surgical resection for HCC, with histological evidence of non-cirrhotic hepatic steatosis after excluding patients with vital hepatitis, alcohol abuse, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, hemochromatosis, alpha-1-antitrypsin deficiency, and Wilson disease (20). The study revealed that 80% of cases were associated with stage 0 liver fibrosis and only 15% had steatohepatitis (20).

**Pathophysiology**

Although our understanding of the pathogenesis of NAFLD-HCC remains limited, several proposed mechanisms have been described including dysregulation of cell growth and chronic inflammation in the setting of hyperinsulinemia, genetic risk including variations of patatin-like phospholipase domain-containing protein 3 (PNPLA3), and more recently selective CD4+ T lymphocyte loss (6, 14, 28-37).

*Tumor Growth*

Uninhibited and dysregulated cell growth in the setting of hyperinsulinemia has been described as a function of insulin-like growth factor-1 (IGF1), mannose 6-phosphate/insulin-like growth factor-2 receptor (M6P/IGF2R), and insulin receptor substrate-1 (IRS-1) (14, 33, 34). IGF1, a peptide hormone upregulated in hyperinsulinemia, facilitates cellular proliferation and inhibits cell death (14). The M6P/IGF2R, a tumor-suppressor gene, regulates cell growth by inhibiting cell proliferation and promoting apoptosis via transforming growth factor-beta and insulin-like growth factor-2, respectively (34). Interestingly, mutations of M6P/IGF2R are seen in HCC and have been identified even in the absence of viral hepatitis and liver cirrhosis (34). IRS-1, an intracellular protein that promotes cell growth via cytokine signaling, is overexpressed (>200%) in HCC tumors which induces a downstream signaling effect that promotes tumor cell growth and enhances tumor progression (33).

*Inflammatory Cascade*

Hyperinsulinemia also triggers an inflammatory milieu involving free fatty acids (FFA), proinflammatory cytokines, reactive oxidative species (ROS), c-Jun amino-terminal kinase 1 (JNK1), and adiponectin (14, 30-32, 35). A high insulin state promotes release of FFA from adipocytes, which promotes steatosis, and in the setting of inflammation fostered by proinflammatory cytokines, can lead to cirrhosis and HCC (14).

Accelerated production of proinflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), nuclear factor-kappa B, resistin, and leptin, promotes a chronic cycle of hepatocyte injury, apoptosis, and compensatory proliferation in conditions of inflammation and oxidative stress that can lead to mutations, dysplasia, and eventually carcinogenesis (14). A study by Park et al. described HCC development in the setting of obesity as a function of enhanced TNF-α and IL-6 expression (31). In addition to causing hepatic inflammation, both cytokines activate signal transducer and activator of transcription 3 (STAT3), an oncogenic transcription factor, which can enhance proliferation and progression of hepatocytes that can acquire oncogenic mutations that lead to tumor development (31). Interestingly, leptin has been described in liver carcinogenesis via upregulation of telomerase reverse transcriptase leading to immortalization of tumor cells in HCC (32).

ROS are implicated in carcinogenesis through dysregulation of the cell cycle (35). A mouse model demonstrated that mitochondria in fatty livers have accelerated production of superoxide anions as compared with mitochondria in normal livers (35). A case report from Japan described a patient without cirrhosis and with NAFLD-associated HCC that had localized markers of oxidative cellular injury (e.g. anti-oxidized phosphatidylcholine) in tumorous and non-tumorous steatotic hepatocytes, which suggests that the prevalence and persistence of oxidative injury in the setting of steatosis is related to the development of HCC (38). Therefore, the presence of increased oxidative species as a suspected function of chronic cell stress is associated with cell injury, apoptosis, and compensatory proliferation, which can enhance mutation formation and cancer cell growth.

*JNK1*

The combination of proinflammatory cytokines, ROS, and FFA activates JNK1, a protein kinase that has increased activity in the setting of obesity and insulin resistance, and in turn phosphorylates IRS-1 (30). JNK1 has been demonstrated to promote development and proliferation of HCC through epigenetic mechanisms (29). Chang et al. described the association of JNK1 activity with alterations in histone H3 methylation in HCC, which leads to sustained expression of genes that promote cell proliferation and repression of genes responsible for cell differentiation and tumor suppression (29).

*Adiponectin*

A decreased amount of adiponectin, an anti-inflammatory polypeptide, in the setting of obesity has also been described in HCC pathogenesis (14, 28). Adiponectin has been identified as a negative regulator of angiogenesis and inhibitor of primary tumor growth via decreased neovascularization and enhancement of tumor cell apoptosis (28). Repression of adiponectin activity in the setting of hyperinsulinemia allows uninhibited tumor cell growth, which can subsequently lead to HCC in NAFLD.

*Genetic Risk: PNPLA3*

Another mechanism that has been associated with the pathogenesis of NAFLD-HCC focuses on genetic risk, specifically variation in PNPLA3. A genome-wide association analysis of 9,229 genetic variants of PNPLA3 revealed that homozygous carriers of the I148M variant protein of PNPLA3 had a >2-fold higher hepatic fat content than noncarriers (39). Furthermore, the I148M variant protein was more prevalent in the group at highest risk of NAFLD (39). Similarly, a study by Liu et al. identified that the PNPLA3 rs738409 C🡪G single nucleotide polymorphism, which encodes the I148M variant protein, demonstrated a gene-dosage effect in which an increased number of G alleles present (i.e. homozygous G allele) was associated with an increased incidence of NAFLD-HCC with an odds ratio as high as 12.19 when compared with the general UK population (36). Interestingly, the PNPLA3 rs738409 C🡪 G polymorphism was associated with NAFLD-HCC risk independent of the presence of cirrhosis (36).

*Selective Loss of CD4+ T Lymphocytes*

A recent study revealed a potential role of the adaptive immune system, specifically CD4+ T lymphocytes, in the development of NAFLD-HCC (37). Ma et al. demonstrated in mouse models of NAFLD-HCC that selective CD4+ T lymphocyte depletion results from NAFLD and leads to enhanced hepatocarcinogenesis. Hepatocytes derived from NAFLD-HCC mice exhibited increased linoleic acid secretion, which promoted selective CD4+ T lymphocyte death through increased mitochondrial-derived ROS generation. While deregulated lipid metabolism and inflammation have been characterized in NAFLD, the role of hepatocyte-derived lipid secretion causing selective CD4+ T lymphocyte loss highlights a novel function of the adaptive immune system in this disease.

**Presentation at Diagnosis**

Patients with NAFLD-HCC generally have a more advanced presentation of HCC at the time of diagnosis (14, 27, 40, 41). A VA cohort study by Mittal et al. revealed that in comparison to HCV-related HCC, fewer cases of NAFLD-HCC were diagnosed in early HCC stages or Barcelona Clinic Liver Cancer (BCLC) stage A (5.8% vs. 15.7%, *p*-value 0.04) and more cases were diagnosed in terminal stages of HCC or BCLC stage D (19.2% vs. 16.1%, *p*-value 0.04) (40). A recent study by Piscaglia et al. also revealed a significantly greater proportion of patients with NAFLD-HCC who presented in advanced stages as compared with patients with HCV-HCC (BCLC stage C 33.1% vs. 23.9%, respectively, *p*-value 0.033) (27). Another recent European cohort study observed a trend towards larger tumor size (median 6 cm vs. 4.8 cm, *p*-value 0.176) with a higher rate of distant metastasis (11.1% vs. 8.1%, *p*-value 0.423) and multifocal disease (80% vs. 69.7%, *p*-value 0.565) at the time of diagnosis among patients with NAFLD-HCC as compared with those with non-NAFLD-HCC secondary to HCV, HBV, ALD, or other liver conditions, although these differences were not statistically significant (41).

Advanced stage at presentation among NAFLD-HCC patients is likely attributable to delayed diagnosis in the setting of suboptimal HCC surveillance among patients with cirrhosis and no surveillance among patients without cirrhosis or unrecognized cirrhosis (27, 40). In an Italian cohort study, a significantly lower proportion of patients with NAFLD-HCC underwent surveillance as compared with those with HCV-HCC (47.6% vs. 63.3%, *p*-value 0.001) (27). In the U.S., Mittal et al. reported that fewer patients with NAFLD-HCC had surveillance within three years before their HCC diagnosis as compared with patients with ALD and HCV (40). Approximately 43% in the NAFLD-HCC group had HCC surveillance within three years of diagnosis as compared with 60% and 87% in the ALD- and HCV-related HCC groups, respectively (40).

**Curative Treatment and Outcomes**

Recipients of curative treatment, which includes orthotopic liver transplantation (OLT), resection, and radiofrequency ablation (RFA), have favorable survival outcomes (3). In concurrence with the growing incidence of NAFLD-HCC, studies have reported an increasing demand for curative treatment, especially OLT and resection (42, 43). NAFLD has become the second leading etiology among OLT cases for HCC since 2006 (42). Wong et al. reported that OLT for NAFLD-HCC has increased four-fold in the US from 2002 to 2012 (42). Over the past decade, the proportion of resections of HCC in the setting of NAFLD has also increased (43). A study by Cauchy et al. demonstrated a continuous increase in the number of patients undergoing resection for HCC from 2.5% in 2000 to more than 15% in 2011 (43).

Interestingly, patients with NAFLD-HCC have been recognized as less likely recipients of curative therapy (7, 40). In a VA cohort, only 10.8% of the NAFLD-HCC group received curative treatment as compared with 21.9% of the HCV-related HCC group (40). Furthermore, in comparison to the HCV-related group, more patients in the NAFLD-HCC group received no treatment (77.5% vs. 61.5%)(40). A large U.S. population-based study using SEER data revealed that 5.7% of patients with NAFLD-HCC received OLT as compared with 11.3%, 6.4%, and 6% of patients with HCC secondary to HCV, HBV, and ALD, respectively (7). Similarly, a European cohort revealed that none of its 45 cases of NAFLD-HCC received OLT as primary therapy (41).

***Survival Outcomes from Curative Treatment***

Data on outcomes of patients who receive curative therapy for NAFLD-HCC remain scarce as most available studies are limited to small sample sizes, surrogate diagnoses of NAFLD (i.e. metabolic syndrome, cryptogenic cirrhosis), or grouped treatment outcomes (i.e. OLT, resection, RFA combined). Based on the available data, the recurrence and survival rates of NAFLD-HCC appear similar to other etiologies of HCC who undergo treatment with curative intent (27, 43-49)(Table 1).

*Orthotopic Liver Transplantation for NAFLD-HCC*

A U.S. cohort study of patients who underwent curative treatment for HCC identified 20 patients who received OLT for NAFLD-HCC and 83 who received OLT for HCC secondary to HCV and/or ALD (45). No significant difference existed in disease-free survival and overall survival in patients who received OLT for HCC over a median follow-up of 50 months (45).

In a retrospective cohort using United Network for Organ Sharing (UNOS) data from 2002 to 2012, Wong et al. reported comparable survival rates at one, three, and five years between those who received OLT for HCC secondary to NAFLD, HCV, ALD, or HCV and ALD (*p*-value 0.99) (47). Survival at one year post-OLT for HCC was 87.5% for nonalcoholic steatohepatitis (NASH) (vs. 88.5% for HCV, 90.2% for ALD, 88.7% for HCV and ALD) (47). At three years, survival for NAFLD-HCC was 79.8% as compared with 73.9%, 73.3%, and 75% for HCV, ALD, and HCV and ALD, respectively (47). Five-year survival data remained similar between all etiologies of HCC in the cohort: 65.5% for NAFLD, 65.7% for HCV, 63.9% for ALD, and 65.7% for HCV and ALD (47). Rates of graft survival were also not significantly different between all HCC etiologies and patient survival was similar across groups (84.3%, 77%, and 63.1% at year one, three, and five, respectively for NAFLD-HCC) (47).

Another U.S. cohort study by Malik et al. retrospectively reviewed 17 patients with NASH-related cirrhosis who underwent OLT with and without known HCC (44). When compared with the group of patients with NASH-related cirrhosis without HCC, the group with NAFLD-HCC had similar survival (88%) over a mean follow-up period of 2.5 years (44).

A Canadian retrospective cohort study described disease-free survival in 81 cases of liver transplant recipients, which included 64 with HCV-related HCC and 17 patients with NAFLD-HCC (48). Over a 10-year follow-up period, disease-free survival in the HCV and NAFLD groups were approximately 65% and 85%, respectively (*p*-value 0.11) (48). While the NAFLD group had a similar number of tumors and cumulative size of tumors as compared with the HCV group, the NAFLD group had a significantly lower proportion of patients with vascular invasion and poorly differentiated HCC (48). Therefore, NAFLD-HCC can have favorable, and potentially better tumor recurrence rates than their HCV counterparts as demonstrated by their trend towards greater disease-free survival (85% vs. 65%) in the setting of less aggressive HCC presentation at diagnosis.

*Orthotopic Liver Transplantation for NAFLD-Cirrhosis*

Literature on post-OLT outcomes among those who undergo transplantation for NAFLD-HCC remains limited. Given the comparable rates of post-OLT survival between those who undergo transplantation for NALFD-related cirrhosis without HCC and those with HCC, inclusion of a few relevant studies that assessed post-OLT outcomes in the setting of NASH and not specifically HCC may provide supplementary information (50-52).

A retrospective cohort study at a single large transplant center in the US compared post-OLT outcomes for NASH cirrhosis and alcoholic cirrhosis (50). Estimates of patient survival at nine years post-OLT were comparable between those who received transplantation for alcoholic cirrhosis or biopsy- or ultrasound-confirmed NASH (*p*-value 0.30) (50). Survival at one, three, five, and nine years were 78%, 78%, 78%, and 52%, respectively, in the NASH group vs. 92%, 86%, 86%, and 76%, respectively, in the alcoholic cirrhosis group. Rates of graft failure were similar between both groups (24% in NASH vs. 18% in alcoholic cirrhosis group, *p*-value 0.40) (50). Acute rejection (41% vs. 23%) and recurrent steatohepatitis (33% vs. 0%) were significantly more common in the NASH group as compared with the alcohol group; however, neither complication was associated with higher rates of re-transplantation (50).

A U.S. cohort study by Yalamanchili et al. retrospectively identified patients who underwent OLT for cryptogenic cirrhosis (N=239) or NASH-related cirrhosis (N=18) after biopsy confirmation and exclusion of HCV and alcoholic cirrhosis (51). In comparison to a miscellaneous group that included other indications for OLT, survival at one, five, 10, and 20 years was similar (85.6% vs. 86.3%, 71.4% vs. 69.9%, 56.5% vs. 52.7%, 12.6% vs. 20.6%, respectively between the cryptogenic/NASH group vs. miscellaneous group) (51). Post-OLT mortality was more likely from cardiovascular disease (21.2% vs. 14.1% of deaths) and less likely from recurrent liver disease (0.7% vs. 10.2%) in patients with cryptogenic/NASH cirrhosis as compared with those who underwent transplantation for other indications (51).

An analysis of outcomes for primary OLT from the Scientific Registry of Transplant Recipients (SRTR) database from 2001 to 2009 compared 1,959 patients who underwent OLT for NASH with 33,822 patients who had OLT for other indications including cryptogenic cirrhosis, HCV, ALD, HBV, primary biliary cholangitis, primary sclerosing cholangitis, and autoimmune hepatitis (52). One- and three-year survival was not significantly different between post-OLT patients who underwent transplant for NASH (84%, 78%) vs. cryptogenic cirrhosis (86%, 79%) vs. others (87%, 78%) (*p*-value 0.67) (52). Graft survival remained similar and comparable between all groups (76% for NASH at three years) (52).

*Liver Resection for NAFLD-HCC*

In addition to OLT, outcomes of liver resections have been studied for NAFLD-HCC (43, 46). Cauchy et al. assembled a cohort of 62 patients with HCC in the setting of metabolic syndrome as a surrogate for NAFLD after exclusion of other etiologies of HCC including HCV, HBV, ALD, hemochromatosis, and autoimmune liver disease who underwent surgical resection (43). Overall survival and disease-free survival rates were 83% and 83%, respectively, at one year and 75% and 70%, respectively, at three years (43).

In a Japanese cohort study, a group of 17 patients with NAFLD was compared with a group with HCV or HBV who underwent surgical resection for HCC (46). Overall survival was 59%, 57%, and 63% in the patients with NAFLD-HCC, HCV-related HCC, and HBV-related HCC, respectively, after five years post-resection, and was not significantly different among the three groups (46). On the contrary, five-year disease-free survival was significantly better in the NAFLD-HCC group as compared with the HCV and HBV groups (66% vs. 29% vs. 39%) (46).

Another Japanese study by Takuma et al. described disease-free and overall survival among HCC cases secondary to cryptogenic cirrhosis as a surrogate for NAFLD vs. HCV (49). All patients received some form of curative treatment for HCC except for OLT, which included RFA, percutaneous ethanol injection, or microwave coagulation therapy (49). Over a mean follow-up of 49 months, those with NAFLD-HCC had significantly lower tumor recurrence rates (39% vs. 71%, *p*<0.001) and significantly higher 5-year survival rates (80% vs. 61%, *p*-value 0.02) as compared with their HCV counterparts (49). While the NAFLD-HCC group had a significantly greater proportion of patients with larger tumors (2.0 vs. 2.8 cm) than the HCV-related HCC group, all were within Milan criteria (49). Therefore, patients with NAFLD-HCC can have improved and better disease-free and overall survival as compared with patients with HCV-associated HCC contingent that they present with early-stage HCC.

***Postoperative Complications***

While long-term disease-free and overall survival among patients with NAFLD-HCC who receive curative therapy is favorable, some studies have reported increased rate of postoperative morbidity and mortality post-hepatectomy in the setting of higher NAFLD activity score (NAS) or cirrhosis (43, 46).

In a study by Cauchy et al., outcome comparisons were made between (1) patients without severe fibrosis and NAS<2 and (2) patients with severe fibrosis (stage F3 or F4) or with a NAS≥2 (43). Aside from having a higher body mass index (BMI) in the latter group (median BMI 31.1 vs. 28.4 kg/m2), no preoperative clinical characteristics or operative characteristics differed between the two groups (43). The group with severe fibrosis or higher NAS had significantly higher rates of 90-day mortality (18% vs. 0%), liver-related complications (32% vs. 4%), and cardiorespiratory complications (37% vs. 13%) (43). Interestingly, multivariate analysis showed that severe underlying fibrosis was not a risk factor for major complications; however, a NAS of two or greater was associated with increased major complications (43)

Wakai et al. reported significantly higher rates of postoperative morbidity and 30-day mortality among patients with NAFLD-HCC as compared with those of other HCC etiologies including HBV or HCV (46). Postoperative morbidity was seen in 59% of the NAFLD group vs. 31% and 28% of the HCV and HBV groups, respectively (46). In the NAFLD group of 10 patients who had postoperative complications, the most common complication was hepatic insufficiency, which was observed in four patients (46). Mortality at 30 days postoperatively was 12%, 0.7%, and 3.3% in the NAFLD, HCV, and HBV groups, respectively (46). The two patients who died in the NAFLD group had underlying NAFLD-related cirrhosis (46).

Therefore, postoperative morbidity and mortality may be enhanced in the setting of inflammatory processes as suggested by the association between postoperative complications and higher NAS and cirrhosis.

**Overall Survival**

Patients with NAFLD-HCC are recognized to have worse prognosis related to advanced stage of HCC at presentation and lower eligibility for curative treatment (7, 27). In a recent SEER cohort study, patients with NAFLD-HCC appeared to have poorer prognosis than patients with viral HCC as demonstrated by a shorter survival time and poorer 1 year survival rate from time of diagnosis (61% vs. 50%, *p*-value <0.0001) (7). A large Italian study by Piscaglia et al. showed that survival was significantly shorter in NAFLD-HCC as compared with HCV-related HCC (25.5 vs. 33.7 months, *p*-value 0.017) which was mainly attributable to later stage of HCC at time of diagnosis (27). Interestingly, in the same study, survival difference disappeared after matching NAFLD-HCC and HCV-related HCC by curative treatment (34.2 vs. 40.8 months, respectively, *p*-value 0.073).

A study by Reddy et al. assessed severity of liver dysfunction and stage of HCC at diagnosis and long-term survival in patients with NAFLD-HCC vs. HCV- and/or ALD-HCC (45) At time of HCC diagnosis, patients with NAFLD-HCC had significantly better hepatic function as compared with the HCV- and ALD-related HCC group (45). There were no significant differences in previous HCC therapy and tumor characteristics at time of diagnosis, including largest tumor size, presence of satellite lesions, stage T3-4 disease (based on American Joint Committee on Cancer staging), and vascular invasion (45). Subsequently, no differences existed between receipt of curative treatment between the two groups (NAFLD vs. HCV and/or ALD) (45). While recurrence-free survival was not significantly different between patients with NAFLD- and HCV/ALD-related-HCC, those with NAFLD-HCC had longer overall survival (45). While having less liver dysfunction at baseline may have contributed to overall improved survival in the NAFLD-HCC group, multivariate analysis adjusting for clinical factors and curative treatment continued to demonstrate that patients with NAFLD-HCC had longer overall survival (45). Therefore, after controlling for disease presentation and receipt of curative therapy, patients with NAFLD-HCC experienced better long-term survival.

A European cohort study showed a non-significant difference of overall survival between patients with NAFLD-HCC vs. those with non-NAFLD-HCC (median 11.28 vs. 15.5 months, *p*-value 0.287) (41). In this cohort, there was no significant difference in receipt of curative treatment and no difference of BCLC stage at time of HCC diagnosis (41). Similarly, a compilation of case reports of NAFLD-HCC of predominantly early-stage HCC (single tumors approximately 3cm in largest size) revealed that all cases without tumor recurrence or death over a 5-50 month follow-up period received a form of curative therapy (53). Therefore, patients with NAFLD-HCC can have favorable survival contingent that they are diagnosed at early stages of HCC and receive curative treatment.

**Future Directions**

Our review highlights recent updates on NAFLD-HCC epidemiology, pathophysiology, disease presentation, demand and receipt of curative treatment, outcomes from curative treatment as compared with other etiologies of HCC, and overall survival. Current literature suggests that NAFLD-associated HCC incidence is increasing, may often occur in the absence of cirrhosis, and present at a more advanced stage, and thereby patient with NAFLD-HCC are less likely to be subject to curative treatment modalities relative to other etiologies of HCC. However, OLT for NAFLD-associated HCC has increased four-fold over the past decade, and post-transplant survival appears to be similar to other HCC-based indications for OLT.

Although the literature addressing NAFLD-HCC is growing, there are several areas which represent high priorities for further research. More robust epidemiological studies to identify high-risk groups for NAFLD-HCC incidence and NAFLD-related mortality may help inform future surveillance and treatment strategies. Additional investigation into mechanisms and determinants of HCC development in non-cirrhotic NAFLD versus NASH may provide critical insight to support evidence-based guidelines on HCC surveillance. Further studies addressing surgical and transplant outcomes among patients with NAFLD and NASH-associated HCC may also guide clinicians and the transplant community on optimal organ allocation and post-transplant management. Significant opportunity exists to address key deficits in knowledge regarding epidemiology, pathogenesis, treatment, and surgical outcomes of NAFLD-associated HCC which remains a rapidly growing global public health problem.

**References**

1. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-1491.

2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576.

3. Njei B, Rotman Y, Ditah I, Lim JK. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology 2015;61:191-199.

4. Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, Henley SJ, et al. Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer 2016.

5. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002;36:1349-1354.

6. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015;313:2263-2273.

7. Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M, Hunt S. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 2015;62:1723-1730.

8. Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol 2007;17:863-869.

9. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011;140:124-131.

10. Goh GB, McCullough AJ. Natural History of Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2016;61:1226-1233.

11. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-140.

12. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012;142:1592-1609.

13. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 2009;115:5651-5661.

14. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010;51:1820-1832.

15. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 2011;54:463-471.

16. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012;10:1342-1359 e1342.

17. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.

18. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010;51:1972-1978.

19. Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, Adams LA, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011;54:1208-1216.

20. Alexander J, Torbenson M, Wu TT, Yeh MM. Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: a clinical and pathological study. J Gastroenterol Hepatol 2013;28:848-854.

21. Guzman G, Brunt EM, Petrovic LM, Chejfec G, Layden TJ, Cotler SJ. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med 2008;132:1761-1766.

22. Kawada N, Imanaka K, Kawaguchi T, Tamai C, Ishihara R, Matsunaga T, Gotoh K, et al. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol 2009;44:1190-1194.

23. Mittal S, El-Serag HB, Sada YH, Kanwal F, Duan Z, Temple S, May SB, et al. Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2016;14:124-131 e121.

24. Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, Ratziu V, et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol 2013;59:550-556.

25. Perumpail RB, Wong RJ, Ahmed A, Harrison SA. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience. Dig Dis Sci 2015;60:3142-3148.

26. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015;13:643-654 e641-649; quiz e639-640.

27. Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, Tiribelli C, Bellentani S, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Hepatology 2016;63:827-838.

28. Brakenhielm E, Veitonmaki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, Funahashi T, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A 2004;101:2476-2481.

29. Chang Q, Zhang Y, Beezhold KJ, Bhatia D, Zhao H, Chen J, Castranova V, et al. Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer. J Hepatol 2009;50:323-333.

30. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M, et al. A central role for JNK in obesity and insulin resistance. Nature 2002;420:333-336.

31. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010;140:197-208.

32. Stefanou N, Papanikolaou V, Furukawa Y, Nakamura Y, Tsezou A. Leptin as a critical regulator of hepatocellular carcinoma development through modulation of human telomerase reverse transcriptase. BMC Cancer 2010;10:442.

33. Tanaka S, Mohr L, Schmidt EV, Sugimachi K, Wands JR. Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes. Hepatology 1997;26:598-604.

34. Yamada T, De Souza AT, Finkelstein S, Jirtle RL. Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. Proc Natl Acad Sci U S A 1997;94:10351-10355.

35. Yang S, Zhu H, Li Y, Lin H, Gabrielson K, Trush MA, Diehl AM. Mitochondrial adaptations to obesity-related oxidant stress. Arch Biochem Biophys 2000;378:259-268.

36. Liu YL, Patman GL, Leathart JB, Piguet AC, Burt AD, Dufour JF, Day CP, et al. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol 2014;61:75-81.

37. Ma C, Kesarwala AH, Eggert T, Medina-Echeverz J, Kleiner DE, Jin P, Stroncek DF, et al. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature 2016;531:253-257.

38. Ikura Y, Mita E, Nakamori S. Hepatocellular carcinomas can develop in simple fatty livers in the setting of oxidative stress. Pathology 2011;43:167-168.

39. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461-1465.

40. Mittal S, Sada YH, El-Serag HB, Kanwal F, Duan Z, Temple S, May SB, et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol 2015;13:594-601 e591.

41. Weinmann A, Alt Y, Koch S, Nelles C, Duber C, Lang H, Otto G, et al. Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. BMC Cancer 2015;15:210.

42. Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 2014;59:2188-2195.

43. Cauchy F, Zalinski S, Dokmak S, Fuks D, Farges O, Castera L, Paradis V, et al. Surgical treatment of hepatocellular carcinoma associated with the metabolic syndrome. Br J Surg 2013;100:113-121.

44. Malik SM, Gupte PA, de Vera ME, Ahmad J. Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma. Clin Gastroenterol Hepatol 2009;7:800-806.

45. Reddy SK, Steel JL, Chen HW, DeMateo DJ, Cardinal J, Behari J, Humar A, et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology 2012;55:1809-1819.

46. Wakai T, Shirai Y, Sakata J, Korita PV, Ajioka Y, Hatakeyama K. Surgical outcomes for hepatocellular carcinoma in nonalcoholic fatty liver disease. J Gastrointest Surg 2011;15:1450-1458.

47. Wong RJ, Chou C, Bonham CA, Concepcion W, Esquivel CO, Ahmed A. Improved survival outcomes in patients with non-alcoholic steatohepatitis and alcoholic liver disease following liver transplantation: an analysis of 2002-2012 United Network for Organ Sharing data. Clin Transplant 2014;28:713-721.

48. Hernandez-Alejandro R, Croome KP, Drage M, Sela N, Parfitt J, Chandok N, Marotta P, et al. A comparison of survival and pathologic features of non-alcoholic steatohepatitis and hepatitis C virus patients with hepatocellular carcinoma. World Journal of Gastroenterology 2012;18:4145-4149.

49. Takuma Y, Nouso K, Makino Y, Gotoh T, Toshikuni N, Morimoto Y, Shimomura H, et al. Outcomes after curative treatment for cryptogenic cirrhosis-associated hepatocellular carcinoma satisfying the Milan criteria. Journal of Gastroenterology & Hepatology 2011;26:1417-1424.

50. Bhagat V, Mindikoglu AL, Nudo CG, Schiff ER, Tzakis A, Regev A. Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. Liver Transpl 2009;15:1814-1820.

51. Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl 2010;16:431-439.

52. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011;141:1249-1253.

53. Page JM, Harrison SA. NASH and HCC. Clin Liver Dis 2009;13:631-647.

**Table 1. Survival Outcomes for Presumed NAFLD-HCC Undergoing Curative Therapies : Summary of Studies**

OLT, orthotopic liver transplantation; RFA, radiofrequency ablation; PEI, percutaneous ethanol injection; MCT, microwave coagulation therapy

aTotal cohort underwent one treatment unless otherwise specified.

bFour patients had both RFA and resection.

cSurvival rates were not reported in the text. Estimates are determined from the Kaplan Meier figures.

dTotal number of NAFLD-HCC cases was not reported as analysis of outcomes among HCC cases secondary to NAFLD was done in a subanalysis. Total HCC cases in the cohort was 5,326.

eMetabolic syndrome was used as a surrogate for NAFLD after exclusion of chronic hepatitis B or C infection, excessive alcoholic consumption, alcoholic liver disease, and hemochromatosis.

fCryptogenic cirrhosis was used as a surrogate for NAFLD after exclusion of chronic hepatitis B or C infection, alcohol consumption, primary biliary cholangitis, autoimmune hepatitis, primary sclerosing cholangitis, alpha 1-antitrypsin deficiency, Wilson’s disease, and hemochromatosis.